Department of Anesthesiology and Resuscitology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Department of Anesthesiology, Mie University Hospital, Mie, Japan, 2-174 Edobashi,Tsu, Japan.
Transplant Proc. 2024 Jul-Aug;56(6):1353-1358. doi: 10.1016/j.transproceed.2024.02.021. Epub 2024 Jul 27.
To compare the clinical benefit of using albumin versus crystalloids for volume resuscitation on organ function in adult patients after liver transplantation.
A retrospective cohort study SETTING: Data from a tertiary care facility electronic medical records on liver transplantation patients admitted to the intensive care unit (ICU).
Adults admitted to the ICU after liver transplantation.
Crystalloid fluid resuscitation compared to albumin 5% in the immediate postoperative period after liver transplant.
Adults who underwent liver transplant surgery and received a 5% albumin solution were compared with those who received a crystalloid solution. Demographic, etiology, clinical variables, perioperative, and outcome variables were collected. The data were analyzed using the t test, two-way analysis of variance, and multivariate analysis. After applying all the exclusion criteria, the study group comprised 57 adult patients (30 males; 52.6%) who underwent liver transplantation, including 27 patients in the crystalloid group (47.4%) and 30 patients in the albumin group (52.6%). The mean patient age was 52.2 years. Patient characteristics were similar in the 2 groups. Daily Sequential Organ Failure Assessment (SOFA) scores decreased gradually during the postoperative period in both groups, and the trend in SOFA scores was similar in the 2 groups. Analysis showed no statistical difference in SOFA score between the 2 groups postoperatively (P = .84). Multivariate linear regression analysis identified the Model for End-stage Liver Disease (MELD) score as a predictor of the 7-day postoperative SOFA score in this population.
In this study, the use of albumin or crystalloid solution in patients undergoing liver transplantation appeared to have no significant difference in terms of the risk of organ dysfunction. However, further research is needed to confirm these findings and fully understand the potential benefits and risks of using either type of fluid.
比较肝移植术后成人患者使用白蛋白与晶体液进行容量复苏对器官功能的临床获益。
回顾性队列研究,设定:三级护理设施电子病历中肝移植患者入住重症监护病房(ICU)的数据。
肝移植后入住 ICU 的成年人。
肝移植后即刻给予晶体液与白蛋白 5%复苏。
比较了接受肝移植手术并接受 5%白蛋白溶液的成年人与接受晶体溶液的成年人。收集了人口统计学、病因、临床变量、围手术期和结局变量。使用 t 检验、双向方差分析和多变量分析对数据进行分析。应用所有排除标准后,研究组包括 57 例接受肝移植的成年患者(男性 30 例;52.6%),其中晶体组 27 例(47.4%),白蛋白组 30 例(52.6%)。患者平均年龄为 52.2 岁。两组患者的特征相似。两组术后每日序贯器官衰竭评估(SOFA)评分逐渐下降,SOFA 评分趋势相似。两组术后 SOFA 评分无统计学差异(P =.84)。多变量线性回归分析确定终末期肝病模型(MELD)评分是该人群术后 7 天 SOFA 评分的预测因子。
在这项研究中,肝移植患者使用白蛋白或晶体液似乎在器官功能障碍风险方面没有显著差异。然而,需要进一步的研究来证实这些发现,并全面了解使用任何类型液体的潜在益处和风险。